LANCL1 Human Pre-designed siRNA Set A contains three designed siRNAs for LANCL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LANCL2 Human Pre-designed siRNA Set A contains three designed siRNAs for LANCL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Lanthanum(Ⅲ) chloride is a biochemical reagent that can be used as a biological material or organic compound for life science related research[1].

Lanthanum(Ⅲ) chloride is a biochemical reagent that can be used as a biological material or organic compound for life science related research[1].

LAP3 Human Pre-designed siRNA Set A contains three designed siRNAs for LAP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LAPTc-IN-1 (compound 4) is a competitive inhibitor targeting acidic M17 leucinopeptidase (LAPTc) with Ki=0.27 μM. LAPTc-IN-1 is a potential antagonist of the parasite Trypanosoma cruzi[1].

LAPTM4A Human Pre-designed siRNA Set A contains three designed siRNAs for LAPTM4A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LAPTM4B Human Pre-designed siRNA Set A contains three designed siRNAs for LAPTM4B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LAPTM5 Human Pre-designed siRNA Set A contains three designed siRNAs for LAPTM5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or […]

Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or […]

Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or […]

LARGE1 Human Pre-designed siRNA Set A contains three designed siRNAs for LARGE1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LARGE2 Human Pre-designed siRNA Set A contains three designed siRNAs for LARGE2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LARP1 Human Pre-designed siRNA Set A contains three designed siRNAs for LARP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LARP1B Human Pre-designed siRNA Set A contains three designed siRNAs for LARP1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LARP4 Human Pre-designed siRNA Set A contains three designed siRNAs for LARP4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LARP4B Human Pre-designed siRNA Set A contains three designed siRNAs for LARP4B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LARP6 Human Pre-designed siRNA Set A contains three designed siRNAs for LARP6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LARP7 Human Pre-designed siRNA Set A contains three designed siRNAs for LARP7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LARS1 Human Pre-designed siRNA Set A contains three designed siRNAs for LARS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LARS2 Human Pre-designed siRNA Set A contains three designed siRNAs for LARS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LAS1L Human Pre-designed siRNA Set A contains three designed siRNAs for LAS1L gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Lasiokaurinin (compound 18) is an n-pentane diterpene isolated from the aerial parts of Isodon adenolomus[1].

LASP1 Human Pre-designed siRNA Set A contains three designed siRNAs for LASP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LasR agonist 1 (9) is a LasR agonist, with an EC50 of 0.7 μM. Used for P. aeruginosa research[1].

LasR antagonist 1 (Compound 7) is an antagonist for LasR with an IC50 of 0.4 μM, that modulates the quorum sensing (QS) in the opportunistic pathogen Pseudomonas aeruginosa[1].

LASSBio-873 is an orally active muscarinic cholinergic receptor (mAChR) agonist that crosses the blood-brain barrier. LASSBio-873 has potent analgesic effects on acute and inflammatory pain. The analgesic effect of LASSBio-873 can be inhibited by intrathecal injection of the M2 receptor antagonist methoctramine[1].

LAT Human Pre-designed siRNA Set A contains three designed siRNAs for LAT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LAT2 Human Pre-designed siRNA Set A contains three designed siRNAs for LAT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Lathosterol(Standard) is the analytical standard of Lathosterol. This product is intended for research and analytical applications. Lathosterol is a cholesterol-like molecule. Serum Lathosterol concentration is an indicator of whole-body cholesterol synthesis.

LATS1 Human Pre-designed siRNA Set A contains three designed siRNAs for LATS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LATS2 Human Pre-designed siRNA Set A contains three designed siRNAs for LATS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Lauroylcarnitine chloride enhances the absorption of salmon calcitonin in rats. Also in determining in situ bioavailability, increased availability of Lucifer yellow and decreased expression of claudin-4 protein in the colon[1][2].

Lauryl hydroxysultaine (LHSB), a surfactant, is comprised of a core Sultaine structure with a sulphopropyl quaternary ammonium salt, an alkyl group and a hydroxyl group[1].

LAX1 Human Pre-designed siRNA Set A contains three designed siRNAs for LAX1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LAYN Human Pre-designed siRNA Set A contains three designed siRNAs for LAYN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LBA-3 is a selective, orally active inhibitor for sodium-coupled citrate transporter SLC13A5, with an IC50 of 67 nM. LBA-3 decreases levels of triglyceride and total cholesterol in oleic and palmitic acid (OPA)-stimulated AML12 cells, PCN-stimulated primary mouse hepatocytes and in mouse models, without detectable toxicity. LBA-3 is blood-brain barrier permeable[1].

LBH Human Pre-designed siRNA Set A contains three designed siRNAs for LBH gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LBP Human Pre-designed siRNA Set A contains three designed siRNAs for LBP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Lbp Rat Pre-designed siRNA Set A contains three designed siRNAs for Lbp gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

LBR Human Pre-designed siRNA Set A contains three designed siRNAs for LBR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LBX1 Human Pre-designed siRNA Set A contains three designed siRNAs for LBX1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LBX2 Human Pre-designed siRNA Set A contains three designed siRNAs for LBX2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LC-1-40 is a PROTAC that selectively degrades NUDT1 (DC50=0.97 nM). LC-1-40 selectively inhibits MYCN-induced tumor growth in mouse models. LC-1-40 also induces nucleotide damage and apoptosis in MYCN-associated tumors. LC-1-40 can be used in cancer research[1]. (Red: NUDT1 binder; Blue: CRBN ligand; Black: Linker).

LCA5 Human Pre-designed siRNA Set A contains three designed siRNAs for LCA5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LCAT Human Pre-designed siRNA Set A contains three designed siRNAs for LCAT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.